Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT07372508

Glasgow Low-dose CT and AI-based Diagnostics to Case Find Lung Cancer and Other Cardio-respiratory Long-term Conditions – Feasibility Study

Glasgow Low-dose CT and AI-based Diagnostics to Case Find Lung Cancer and Other Cardio-respiratory Long-term Conditions – Feasibility Study — Recruiting • Non-phase study • Oncology • NCT07372508.

📅 23 Jun 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07372508
Sponsor
NHS Greater Glasgow and Clyde
Start
2026-05-26
ClinicaliQ Trial Snapshot
  • Glasgow Low-dose CT and AI-based Diagnostics to Case Find Lung Cancer and Other Cardio-respiratory Long-term Conditions – Feasibility Study — Recruiting • Non-phase study • Oncology • NCT07372508.
  • What is being tested: Low-dose CT scanning combined with artificial intelligence diagnostics to detect lung cancer early and identify other cardio-respiratory long-term conditions in a Scottish population, assessing the feasibility of implementing this screening approach in NHS settings.
  • Patient eligibility overview: The study targets individuals at risk of lung cancer and cardio-respiratory disease in Glasgow, likely including current and former smokers and those with relevant risk factors, though specific inclusion criteria would be detailed in the full protocol.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Lung cancer is one of the most common and serious cancers in Scotland and is often diagnosed at a late stage. Early detection is crucial to improving survival rates. The value of screening for lung cancer with low-dose CT (LDCT) scans has been established, and these scans can also identify other diagnoses earlier. Additional tests undertaken alongside the CT scan may add value to the lung cancer screening program being rolled out. This study aims to explore the feasibility and utility of a lung cancer screening program with added heart…

Eligibility Snapshot
  • : * Resident in South Sector NHS GG&C. * Capacity to undertake informed consent. * No active cancer other than non-melanoma skin cancer, monitored localised prostate cancer or localised treated breast cancer. * Aged 55-74 at date of invitation. * Smoking history: current tobacco smoker or ex-smoker with >20 pack year history and 200kg). * Unable to lie flat. * People who are pregnant. * Active symptoms of possible lung cancer

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Guideline
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
Oncology · 07 Oct 2026
Trastuzumab deruxtecan is recommended by NICE as a treatment option for HER2-low metastatic or unresectable breast cancer, making it suitable for patients…
View guideline →
Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Clinical Brief
Very hot drinks may damage the food pipe and increase cancer risk
Oncology · BBC Health · 08 Sep 2026
The International Agency for Research on Cancer has classified drinking "very hot" beverages (above 65°C) as probably carcinogenic, with repeated thermal injury…
View brief →
Guideline
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
Oncology · 26 Aug 2026
Test for MSI-H/dMMR before treatment: All patients with advanced or recurrent endometrial cancer should undergo microsatellite instability or mismatch repair deficiency testing…
View guideline →
Clinical Brief
I want to use my mental health experiences to help others – ex-ref Robathan
Oncology · BBC Health · 25 Sep 2026
I notice the article summary appears incomplete (it cuts off mid-sentence after "benign tumours in..."), so I cannot accurately identify the three…
View brief →